Prothena Co. plc (NASDAQ:PRTA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight brokerages that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $51.71.

Several research analysts have weighed in on the stock. JMP Securities dropped their price objective on shares of Prothena from $80.00 to $78.00 and set a "market outperform" rating on the stock in a research note on Friday. Cantor Fitzgerald restated an "overweight" rating on shares of Prothena in a research note on Friday, February 21st. Oppenheimer increased their price target on shares of Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a research note on Friday, February 7th. Chardan Capital restated a "buy" rating and set a $40.00 price target on shares of Prothena in a research note on Friday. Finally, HC Wainwright dropped their price target on shares of Prothena from $48.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtus ETF Advisers LLC grew its stake in Prothena by 19.3% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,148 shares of the biotechnology company's stock valued at $71,000 after buying an additional 833 shares during the last quarter. GAMMA Investing LLC grew its stake in Prothena by 4,626.0% in the 1st quarter. GAMMA Investing LLC now owns 6,002 shares of the biotechnology company's stock valued at $74,000 after buying an additional 5,875 shares during the last quarter. Headlands Technologies LLC grew its stake in Prothena by 196.5% in the 4th quarter. Headlands Technologies LLC now owns 7,330 shares of the biotechnology company's stock valued at $102,000 after buying an additional 4,858 shares during the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Prothena in the 1st quarter valued at $126,000. Finally, Teacher Retirement System of Texas acquired a new position in Prothena in the 4th quarter valued at $145,000. 97.08% of the stock is currently owned by institutional investors and hedge funds.

Prothena Price Performance

Prothena stock traded up $0.33 during trading hours on Tuesday, hitting $7.43. The company had a trading volume of 1,656,948 shares, compared to its average volume of 565,729. The firm has a market capitalization of $399.93 million, a P/E ratio of -3.23 and a beta of 0.11. The firm's fifty day moving average is $11.10 and its 200-day moving average is $13.56. Prothena has a fifty-two week low of $6.92 and a fifty-two week high of $25.42.

Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.20). The company had revenue of $2.83 million during the quarter, compared to analyst estimates of $8.18 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%. The firm's quarterly revenue was up 5500.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.34) EPS. Analysts anticipate that Prothena will post -4.04 earnings per share for the current year.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.